Lupin Ltd Share Price

Q: What is the share price of Lupin Ltd today?

Lupin Ltd share price as on 16 May 2025 is ₹2014.8

Pharmaceuticals

NSE: LUPIN Large Cap ISIN: INE326A01037

As on 16 May 2025 at 20:47 IST

₹ 2,014.80

-56.60

(-2.73%)

Sell Buy

Lupin Q4 and Full-Year FY25 Results:

Net profit more than doubled to ₹772.5 crores, compared to ₹359 crores in Q4 FY24. Total income in Q4 FY25 increased 15% to ₹5,724 crores from ₹4,990 crores in the same period last year. For the financial year 2025, the company reported a net profit of ₹3,282 crores and a total income of ₹22,904 crores, compared with ₹1,914.5 crores and ₹20,131 crores recorded last year, respectively.

About Lupin Ltd

Lupin Limited is a leading Indian multinational pharmaceutical company. It has established itself as a major player in the global healthcare industry. The company was founded by Desh Bandhu Gupta in 1968. It has grown into one of the largest generic pharmaceutical companies worldwide by revenue with decades of experience since its inception. The headquarters of the company is located in Mumbai, Maharashtra, India. Primary products of Lupin Limited include generic drugs, biosimilars, and specialty medicines. The company’s focus spans key therapeutic areas such as pediatrics and anti-tuberculosis treatments. +

Over 1 Month

7.71%

Over 6 Months

-1.90%

Over 1 Year

28.61%

Over 3 Years

182.57%

Lupin Ltd Summary

Close ₹2,071.40

Open ₹2,025.10

High ₹2,074.90

Low ₹2,025.10

Volume 6,87,550

Net Turnover (in Cr) ₹141.84

52Wk High ₹2,402.90

52Wk Low ₹1,493.30

52Wk High / Low

1,493.30

2,402.90

Lupin Ltd Fundamentals

Key Financial Data

Market Cap (in Cr) ₹94,583.55

EPS (TTM) 68.51

Book Value (BV) 481.33

Div. Yield 0.39 %

P/E (TTM) 30.85

Price/Book Value 4.30

Delivery % 61.14 %

Face Value 2

Key Ratios

PE Ratio 31.70

PB Ratio 3.58

EV to Sales 5.02

PEG Ratio 0.07

ROA 11.01

ROE 11.92

Debt-Equity 0.02

Net Profit Margin 15.86

Operating Profit Margin 24.31

Lupin Ltd Financials

Consolidated

Standalone

Yearly

Quarterly

Profit and Loss

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	20,141.50	16,792.57	16,615.57	15,299.25	15,858.52
Total Expenses	17,719.23	16,076.08	17,988.14	13,624.13	14,353.16
Profit Before Tax	2,422.27	716.49	-1,372.21	1,676.45	757.23
Profit After Tax	1,935.57	447.69	-1,509.36	1,227.93	-399.88
Operating Profit After Depreciation	2,733.88	990.79	-1,229.80	1,815.76	1,868.34

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	9,055.16	8,698.41	7,680.43	8,095.48	8,119.57
Total Non Current Assets	10,549.53	10,504.63	9,363.54	9,624.07	9,570.64
Total Current Assets	13,447.65	12,451.30	12,457.68	13,986.37	15,413.21
Total Assets	23,997.18	22,955.93	21,821.22	23,610.44	24,983.85
Total Shareholder's Fund	14,290.29	12,464.50	12,153.27	13,803.14	12,536.70

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash From Operating Activities	3,648.36	1,897.24	367.31	1,821.76	1,468.84
Net Cash Used In Investing Activities	-1,712.20	-1,286.77	1,292.23	-1,239.58	1,106.99
Net Cash Used In Financing Activities	-2,184.21	-337.25	-1,572.32	-1,885.27	-890.58

Profit and Loss

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	14,782.01	11,468.85	11,988.66	11,185.02	11,500.85
Total Expenses	11,997.32	10,941.71	12,150.19	9,555.32	9,689.39
Profit Before Tax	2,784.69	527.14	-161.53	1,629.70	1,052.25
Profit After Tax	2,326.09	425.21	-188.70	1,258.62	727.55
Operating Profit After Depreciation	2,841.04	625.58	-88.06	1,670.32	1,864.05

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	4,147.88	4,210.53	3,863.88	3,793.86	3,641.25
Total Non Current Assets	15,634.99	15,112.75	13,875.55	12,241.19	9,841.99
Total Current Assets	9,287.87	7,570.92	8,437.82	9,617.37	10,838.51
Total Assets	24,922.86	22,683.67	22,313.37	21,858.56	20,680.50
Total Shareholder's Fund	20,603.09	18,411.86	18,150.19	18,565.57	17,473.20

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash From Operating Activities	2,504.13	1,793.99	151.03	1,570.08	2,219.49
Net Cash Used In Investing Activities	-1,599.02	-1,269.17	-371.79	-2,507.52	-739.56
Net Cash Used In Financing Activities	-867.07	-498.26	102.45	-53.17	-367.85

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	5,767.71	5,672.73	5,600.33	4,960.79	5,197.41
Total Expenses	4,411.81	4,332.37	4,359.36	3,963.94	4,159.47
Profit Before Tax	1,071.27	1,054.86	993.03	497.71	736.10
Profit After Tax	858.86	859.48	805.54	368.22	618.70
Operating Profit after Depreciation	1,409.61	1,382.65	1,308.75	1,026.10	1,067.31

Particulars (in ₹ Cr.)	2024-12	2024-09	2024-06	2024-03	2023-12
Total Revenue	4,208	4,106.20	4,167.63	3,395.88	4,115.75
Total Expenses	2,796.95	2,991.45	2,967.96	2,695.53	2,898.41
Profit Before Tax	1,217.06	984.05	1,082.92	428.16	1,083.96
Profit After Tax	984.67	807.76	889.18	384.08	916.44
Operating Profit after Depreciation	1,466.35	1,147.37	1,237.89	731.69	1,240.50

Lupin Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 2,039.37

S2 2,007.33

S3 1,989.57

Pivot 2,057.13

R1 2,089.17

R2 2,106.93

R3 2,138.97

Moving Average

20 SMA 2,022.49

50 SMA 2,009.03

100 SMA 2,081.16

200 SMA 2,094.80

Lupin Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Lupin Ltd

₹8.0/Share

Announcement Date 16 Jul 2024

Record Date 16 Jul 2024

Div Yield 400%

AGM Date: 03 Aug 2022

AGM 03/08/2022 Intimation regarding Annual General Meeting of Lupin Limited on August 3, 2022 Submission of the Integrated Report of the Company for the year ended March 31, 2022 along with the Notice dated May 18, 2022, convening the Fortieth Annual General Meeting of the Company, to be held on Wednesday, August 3, 2022, at 4.00 p.m. (IST) through Video Conferencing/Other Audio-Visual Means. (As Per BSE Announcement dated on 12.07.2022) Proceedings at the 40th Annual General Meeting held on Wednesday, August 3, 2022. (As Per BSE Announcement dated on 03.08.2022) Lupin Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 (As per BSE Announcement Dated on 05/08/2022) Scrutinizer''s Report for declaration of voting results at the Fortieth Annual General Meeting of the Company, held on Wednesday, August 3, 2022, at 4.00 p.m. (IST) through Video Conferencing/Other Audio Visual Means. (As Per BSE Announcement Dated 04.08.2022)

AGM Date: 03 Aug 2023

The Company has fixed Friday, July 14, 2023, as the ''Record Date'' for the purpose of ascertaining the shareholders who will be entitled to payment of Dividend. Forty-First Annual General Meeting to be held on Thursday, August 3, 2023. Proceedings at the 41st Annual General Meeting held on Thursday, August 3, 2023. (As per BSE Announcement Dated on 03/08/2023) Proceedings of the 41st Annual General Meeting. (As Per BSE Announcement Dated on 15/04/2024)

AGM Date: 02 Aug 2024

AGM 02/08/2024 Submission of the Integrated Report of the Company for the year ended March 31, 2024 along with the Notice convening the Forty-Second Annual General Meeting of the Company at 4.00 p.m. (IST) on Friday, August 2, 2024 through Video Conferencing/Other Audio-Visual Means. (As Per BSE Announcement Dated on: 09/07/2024) Proceedings at the 42nd Annual General Meeting of the Company, held today i.e. Friday, August 2, 2024, at 4.00 p.m. (IST) through Video Conferencing/Other Audio-Visual Means. (As Per BSE Announcement dated on 02.08.2024) Details of voting results of the 42ns Annual General Meeting of the Company & Consolidated Scrutiniser''s Report. (As Per BSE Announcement Dated on 03.08.2024)

Lupin Ltd Peer Comparison

Company	Price	Market Cap (in Cr)
Sun Pharmaceutical Industries Ltd	₹1,781.35	₹4,27,405.53
Divis Laboratories Ltd	₹6,144.35	₹1,63,113.19
Cipla Ltd	₹1,508.95	₹1,21,868.90
Torrent Pharmaceuticals Ltd	₹3,289.90	₹1,11,340.16
Mankind Pharma Ltd	₹2,430.05	₹1,00,258.65

Lupin Ltd Top Mutal Funds Invested

Fund Name	AUM
Nippon India Pharma Fund	6.30%
Mirae Asset Midcap Fund	3.02%
AXIS Midcap Fund	2.11%
SBI Long Term Equity Fund	1.97%
HDFC Large Cap Fund	1.89%

Lupin Ltd News

Lupin gets USFDA nod for Eslicarbazepine Acetate tablets

Lupin announced that it has received an approval from US Food and Administration (USFDA) for Eslicarbazepine Acetate Tablets, 200 mg, 400 mg, 600 mg, and 800 mg.

08 May 2025, 08:26 am

Lupin announces board meeting date

On 14 May 2025

30 Apr 2025, 11:10 am

Lupin rallies after receiving USFDA nod for Tolvaptan tablets

Lupin rose 1.09% to Rs 2,111.55 after the global pharmaceutical major received approval from the U.S. Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Tolvaptan Tablets.

24 Apr 2025, 11:40 am

Lupin receives USFDA approval for Tolvaptan Tablets

24 Apr 2025, 11:06 am

Lupin gets EIR from USFDA for Nagpur facility

Lupin announced that it has received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (USFDA) for drug'medical device combination products at its injectable facility in Nagpur, India.

17 Apr 2025, 03:00 pm

Lupin Ltd Stock Analysis

Annual revenue for Lupin Ltd increased by 28.89% to ₹14,782.01 crore in FY 2024 from ₹11,468.85 crore in FY 2023.
Annual Net Profit for Lupin Ltd increased by 447.04% to ₹2,326.09 crore in FY 2024 from ₹425.21 crore in FY 2023.
Promoter Shareholding in Lupin Ltd decreased by 0.07% in the most recent quarter, from 46.95% in December 2024 to 46.92% in March 2025.
Lupin Ltd delivered a 1-year return of 28.61% compared to the Nifty 50, which provided a return of 9.47% as of the last trading session.
Lupin Ltd share price moved down by 2.73% from its previous close of INR ₹2,071.40. The latest Lupin Ltd share price is INR ₹2,014.80.
Lupin Ltd share price today has been at a low of 2,006.70 and a high of 2,099.70. Over the past 52 weeks, the Lupin Ltd share price has seen a low of 1,493.30 and a high of 2,402.90.

About Lupin Ltd

Lupin Limited is a leading Indian multinational pharmaceutical company. It has established itself as a major player in the global healthcare industry since its inception in 1968. With decades of experience, Lupin has grown into one of the largest generic pharmaceutical companies worldwide by revenue.
Headquartered in Mumbai, Maharashtra, Lupin specialises in developing and distributing various healthcare products. Its portfolio includes generic drugs, active pharmaceutical ingredients (APIs), biosimilars, and specialty medicines. The company’s focus spans key therapeutic areas such as paediatrics and anti-tuberculosis treatments.
Founded by Desh Bandhu Gupta, Lupin remains a family-driven enterprise. Vinita D. Gupta serves as CEO, and Nilesh Gupta is the Managing Director. This leadership structure guides Lupin's strategic direction and operations. Lupin’s influence extends far beyond India, with a strong presence in over 100 countries. Key markets include the United States, Europe, Japan, and India. This underscores the company's global reach and impact in the pharmaceutical sector.
Operating from its registered office at Kalpataru Inspire, Mumbai, Lupin continues to expand its market share and product offerings. The registrar’s office is L.B.S. Marg, Vikhroli. It is not currently the top-ranked stock in its sector. However, the company's global revenue cements its position as a major pharmaceutical player.
The Gupta family maintains primary promoter shareholding, providing stability to the company's operations. This family backing positions Lupin as a crucial institution in the pharmaceutical industry. As Lupin navigates the evolving healthcare landscape, it is committed to innovation and global expansion. As a result, it is building on its rich legacy in pharmaceutical development and distribution.

Lupin’s Manufacturing Excellence - Quality at Scale

Lupin Limited has established itself as a benchmark for manufacturing excellence. The company’s commitment to quality and scale is evident in its manufacturing facilities and its rigorous adherence to global standards. This dedication ensures that Lupin consistently delivers high-quality pharmaceutical products to markets worldwide.
Lupin’s manufacturing prowess is built on a foundation of advanced technology. The company operates 15 cGMP-compliant manufacturing facilities across three continents. These facilities are equipped with cutting-edge technology. They also adhere to the highest national and international standards. This ensures the quality, safety, and efficacy of Lupin’s products. The company’s ability to scale its operations is also a testament to its robust infrastructure and strategic investments.
One of the key aspects of Lupin’s manufacturing excellence is its focus on operational efficiency. The company has adopted advanced manufacturing processes, such as continuous flow reactors. These technologies allow for precise control over production parameters. This leads to consistent product quality and significant cost savings. Lupin can accelerate product development by streamlining production processes. This ensures that patients have timely access to essential medications.
Lupin’s commitment to quality is further reinforced by its stringent quality control measures. The company adheres to global quality standards, including cGMP and cGLP norms. Regular inspections and audits by regulatory authorities such as the US FDA, WHO, TGA (Australia), MHLW (Japan) and MCC (South Africa) ensure that Lupin’s manufacturing facilities maintain the highest standards of quality and compliance. This approach to quality control ensures that every product meets the highest standards of purity and safety.
In addition to its focus on quality and efficiency, Lupin places a strong emphasis on sustainability. The company has implemented various measures to reduce its environmental impact. For instance, Lupin’s continuous flow reactors enhance efficiency and reduce the carbon footprint. So, by adopting green chemistry principles and optimising resource utilisation, Lupin ensures that its manufacturing operations are environmentally responsible.
Lupin’s manufacturing excellence is also driven by its commitment to innovation. The company invests heavily in research and development. This is to stay at the forefront of pharmaceutical manufacturing technology. Lupin’s R&D efforts focus on developing new formulations and exploring novel manufacturing techniques. This commitment to innovation enables Lupin to continuously enhance its manufacturing capabilities. It also helps them deliver high-quality products to patients worldwide.
The company’s global supply chain is another critical component of its manufacturing excellence. Lupin’s supply chain operations are aligned with global commercial plans and protocols. This ensures the smooth transfer of inputs into its plants and the timely output of products to consumers worldwide. The company’s ability to maintain high levels of on-time delivery is also a testament to its efficient supply chain management. This ensures the company meets customer needs consistently and competitively.
Lupin’s manufacturing excellence is also reflected in its partnerships and collaborations. The company works closely with contract manufacturing organisations to expand production capacities. These partnerships enable the company to leverage external expertise and resources, further strengthening its manufacturing capabilities. As a result, Lupin stays ahead of industry trends.
Lupin Limited’s manufacturing excellence is due to its commitment to quality and innovation. The company’s quality control measures and advanced manufacturing technologies ensure that it delivers quality pharmaceutical products. Lupin’s focus on continuous improvement and strategic partnerships further enhances its manufacturing capabilities. This has positioned it as a leader in the global pharmaceutical industry.